Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 7/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343832 | 1.00 | ABL1 (0.56) | ABL1RIN1CYP1A2ALDH1A1LMNA | |
| SCHEMBL19146448 | 0.91 | CYP1A2 (0.48) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL19146239 | 0.89 | P2RY12 (0.44) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL19146385 | 0.89 | CYP1A2 (0.44) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL21540034 | 0.88 | P2RY12 (0.44) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL31093228 | 0.88 | SLC29A1 (0.49) | CYP1A2ALDH1A1LMNAMAPK1 | |
| SCHEMBL22907485 | 0.87 | CYP1A2 (0.43) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL21726069 | 0.87 | P2RY12 (0.55) | — | |
| SCHEMBL12652414 | 0.86 | UBA6 (0.47) | ABL1RIN1CYP1A2NR2F2GALR3 | |
| SCHEMBL20792252 | 0.86 | ADORA3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3682903-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3342425-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2019-12-18 | — | — | EP | disclosed |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| WO-2018100558-A2 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | WO | disclosed |
| EP-1667522-B1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORP (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017123669-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | GLICK GARY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9657296-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170130225-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | GERON CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7138383-B2 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity | GERON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1543021-A2 | OLIGONUCLEOTIDE CONJUGATES | Geron Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050049408-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | GERON CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6835826-B2 | Acid resistance, stability; telomerase inhibitor | GERON CORPORATION | 2004-12-28 | — | — | US | disclosed |
| WO-2004029277-A2 | OLIGONUCLEOTIDE CONJUGATES | GERON CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | GERON CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6608036-B1 | Inhibit telomerase enzyme activity; inhibit proliferation of cell that expresses telomerase | GERON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | GERON CORPORATION | 2003-07-24 | — | — | US | disclosed |
| WO-2001074136-A2 | TELOMERASE INHIBITOR POLYNUCLEOTIDES | GERON CORPORATION (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049408-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | RNGTT, MTAP, TYMP | ABL1 2371/4885RIN1 1974/4885CYP1A2 4791/4885 |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | TERT, RNGTT, DUT | ABL1 370/4885RIN1 3535/4885CYP1A2 3936/4885 |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | ABL1 199/4885RIN1 3425/4885CYP1A2 3383/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ABL1 199/4885RIN1 3425/4885CYP1A2 3383/4885 |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | NT5C3B, MTAP, TERT | ABL1 1671/4885RIN1 1719/4885CYP1A2 4876/4885 |
| US-20070037770-A1 | That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits | RNGTT, MTAP, TYMP | ABL1 2371/4885RIN1 1974/4885CYP1A2 4791/4885 |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | ABL1 2210/4885RIN1 3903/4885CYP1A2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.